甲基化转移酶抑制剂zebularine对人子宫内膜癌细胞ECC-1高迁移率族蛋白B1基因表达的影响  

The Effects of Zebularine on HMGB1 mRNA Expression in ECC-1 Cell Line

作　　者：董毅飞[1] 王旭[1] 刁红录[1] 王伟明[1] 张昌军[1] 王华[1] 

机构地区：[1]湖北医药学院附属人民医院生殖医学中心,湖北十堰442000

出　　处：《湖北医药学院学报》2016年第4期342-344,349,共4页Journal of Hubei University of Medicine

摘　　要：目的:研究甲基化转移酶抑制剂zebularine对人子宫内膜癌ECC-1细胞系增殖、迁移及高迁移率族蛋白B1(high mobility group box-1,HMGB1)基因表达的影响。方法:采用MTT法和划痕实验检测zebularine对人子宫内膜癌ECC-1细胞系的增殖抑制率及其细胞迁移率的影响,采用real-time PCR检测作用前后HMGB1 mRNA表达的变化。结果:⑴终浓度为200μmol/L的zebularine作用24 h能显著抑制ECC-1细胞系的增殖率和迁移率。MTT法对照组吸光度为0.64±0.05,实验组为0.46±0.04(P<0.05);对照组划痕愈合率为(87.45±6.05)%,实验组为(45.23±3.45)%(P<0.05);⑵终浓度为200μmol/L的zebularine作用24 h能显著降低HMGB1 mRNA的表达,对照组相对表达量为1.02±0.10,实验组为0.25±0.06(P<0.05)。结论:甲基化转移酶抑制剂zebularine可以有效抑制ECC-1细胞系的增殖和迁移,其效应可能与降低HMGB1 mRNA的表达有关。Objective To study the effects of DNA methylation inhibitor zebularine on the proliferation,migration and high mobility group box-1（ HMGB1） mRNA expression in ECC-1 cell line（ human endometrial carcinoma cell line）. Methods MTT method and wound healing assay were used to evaluate the proliferation and migration level of ECC-1.The mRNA expression of HMGB1 was evaluated by Real-time PCR. Results After treatment with zebularine at a final concentration of200 μmol/L for 24 h,the proliferation and migration of ECC-1 cell lines were significantly inhibited,the absorbance value of MTT method was 0.46±0.04 in the experiment group,which was significantly lower than that in the control group（ 0.64±0.05）,（ P〈0.05）; the wound healing rate was 45.23% ±3.45% in the experiment group,which was significantly lower than that in the control group（ 87.45% ±6.05%）,（ P〈0.05）; the relative mRNA expression of HMGB1 was 1.02±0.10 in control group,and which was significantly higher than that in experiment group（ 0.25±0.06）,（ P〈0.05）.Conclusion DNA methylation inhibitor zebularine could effectively inhibit the proliferation and migration of ECC-1 cell lines,and the effects may relate with the decreasing of HMGB1 mRNA expression.

关 键 词：甲基化转移酶抑制剂 子宫内膜癌 高迁移率族蛋白 

分 类 号：R737.33[医药卫生—肿瘤]